FBLG

8-K - FibroBiologics, Inc. (0001958777) (Filer)

Legendary Sports Agent, Attorney, and Longtime Advocate for Human Longevity and Brain Health Joins BoardHOUSTON, Aug. 24, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the appointment of Leigh Steinberg to its Board of Directors. Widely regarded as the most influential sports agent of his generation, Mr. Steinberg brings five decades of dealmaking experience, a deep commitment to human longevity research, and a long record of initiat

Patent covers the use of cannabidiol in combination with fibroblast-based cell therapy to treat degenerative disc diseaseHOUSTON, Aug. 20, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the acceptance by IP Australia of Australian Patent Application No. 2020368344, entitled "Cannabidiol Adjuvant Therapy for Treatment of Disc Degenerative Disease." The accepted application describes methods of treating degenerative disc disease by admi

Animal trials show cartilage repair within four weeks following a single injection of chondrocyte spheroidsHOUSTON, Aug. 18, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced a breakthrough in its orthopedics laboratory using chondrocyte spheroids to treat degenerative joints. Degenerative joint disease affects millions of people worldwide and is one of the leading causes o

SCHEDULE 13G - FibroBiologics, Inc. (0001958777) (Subject)

Patent has potential for applications beyond diabetes, including other cell and tissue transplantation proceduresHOUSTON, Aug. 11, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,691,147, entitled "Methods and Compositions for Treatment of Type 1 Diabetes Using Fibroblasts in Facilitation of Islet Engraftment." The patent describes methods utilizin

Granted claims cover Sox9-based conversion of fibroblasts into cartilage-producing cells, supporting the Company's orthopedics and degenerative disc pathwaysHOUSTON, Aug. 5, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the European Patent Office (EPO) has granted the Company's patent entitled "Gene Therapy for the Regeneration of Chondrocytes or Cartilage Type Cells."

- First patients dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers- On track for interim results reporting in 2H 2026HOUSTON, July 31, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update. Recent Highlights:Clinical Updates:Initiation of patient dosing in the

10-Q - FibroBiologics, Inc. (0001958777) (Filer)

DEF 14A - FibroBiologics, Inc. (0001958777) (Filer)

8-K - FibroBiologics, Inc. (0001958777) (Filer)

PRE 14A - FibroBiologics, Inc. (0001958777) (Filer)

EFFECT - FibroBiologics, Inc. (0001958777) (Filer)

424B3 - FibroBiologics, Inc. (0001958777) (Filer)

3 - FibroBiologics, Inc. (0001958777) (Issuer)

S-3 - FibroBiologics, Inc. (0001958777) (Filer)

8-K - FibroBiologics, Inc. (0001958777) (Filer)

Microbiologist, Retired NASA Astronaut, and Founding Director of the University of Pittsburgh Trivedi Institute for Space and Global Biomedicine Joins BoardHOUSTON, July 9, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the appointment of Kathleen "Kate" Rubins, Ph.D. to its Board of Directors. As a retired NASA astronaut, microbiologist, and genomics scientist, Dr. Rubins has conducted pioneering medical research on the immune respon

Company expects existing supply will suffice to complete clinical trial and lead to cost savingsHOUSTON, July 7, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced completion of manufacturing of the third batch of its CYWC628 drug product for the ongoing Phase 1/2 clinical trial in patients with diabetic foot ulcers (DFUs). The batch was manufactured in accordance with cGMP

HOUSTON, June 30, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Founder and Chief Executive Officer, Pete O'Heeron, and Chief Scientific Officer, Hamid Khoja, Ph.D., will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference taking place June 30 – July 1, 2026. The fireside

D - FibroBiologics, Inc. (0001958777) (Filer)

8-K - FibroBiologics, Inc. (0001958777) (Filer)

 $3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrantsHOUSTON, June 29, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the closing of its previously announced private placement for the purchase and sale of an aggregate of 4,081,633 shares of common stock (or pre-funded warrants in lieu thereof), series A warrants to purchase up to 4,081,

 $3.0 million upfront with up to approximately $6.0 million of potential additional gross proceeds upon the exercise in full of warrantsHOUSTON, June 26, 2026 /PRNewswire/ -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics" or the "Company"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 4,081,633 shares of common stock (or pre-funded warrants in lieu thereof), series A warrants to purchase up to 4,081,633 shares

4 - FibroBiologics, Inc. (0001958777) (Issuer)